Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
LYVE1 encodes a type I integral membrane glycoprotein. Additionally we are shipping LYVE1 Proteins (36) and LYVE1 Kits (15) and many more products for this protein.
Showing 10 out of 243 products:
Mouse (Murine) Polyclonal LYVE1 Primary Antibody for EIA, FACS - ABIN115689
Jackson: The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. in Trends in cardiovascular medicine 2003
Show all 7 references for ABIN115689
Human Polyclonal LYVE1 Primary Antibody for EIA, IHC (p) - ABIN357391
Cursiefen, Schlötzer-Schrehardt, Küchle, Sorokin, Breiteneder-Geleff, Alitalo, Jackson: Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. in Investigative ophthalmology & visual science 2002
Show all 5 references for ABIN357391
Human Polyclonal LYVE1 Primary Antibody for EIA, FACS - ABIN115663
Mouta Carreira, Nasser, di Tomaso, Padera, Boucher, Tomarev, Jain: LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. in Cancer research 2001
Show all 4 references for ABIN115663
Mouse (Murine) Monoclonal LYVE1 Primary Antibody for FACS, IHC (p) - ABIN1449242
Hirashima, Sano, Morisada, Murakami, Rossant, Suda: Lymphatic vessel assembly is impaired in Aspp1-deficient mouse embryos. in Developmental biology 2008
Show all 4 references for ABIN1449242
Mouse (Murine) Polyclonal LYVE1 Primary Antibody for EIA, FACS - ABIN126137
Sleeman, Krishnan, Kirkin, Baumann: Markers for the lymphatic endothelium: in search of the holy grail? in Microscopy research and technique 2001
Show all 3 references for ABIN126137
Human Polyclonal LYVE1 Primary Antibody for EIA, IHC (p) - ABIN357392
Cunnick, Jiang, Gomez, Mansel: Lymphangiogenesis quantification using quantitative PCR and breast cancer as a model. in Biochemical and biophysical research communications 2001
Show all 3 references for ABIN357392
Human Polyclonal LYVE1 Primary Antibody for IHC (p), WB - ABIN388751
Banerji, Ni, Wang, Clasper, Su, Tammi, Jones, Jackson: LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. in The Journal of cell biology 1999
Show all 2 references for ABIN388751
Human Polyclonal LYVE1 Primary Antibody for WB - ABIN616055
Heindl, Hofmann, Adler, Knorr, Holbach, Naumann, Kruse, Cursiefen: Intraocular tumor-associated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension? in Ophthalmology 2010
Show all 2 references for ABIN616055
Cow (Bovine) Polyclonal LYVE1 Primary Antibody for WB - ABIN2782730
Ishikawa, Akishima-Fukasawa, Ito, Akasaka, Yokoo, Ishii: Histopathologic determinants of regional lymph node metastasis in early colorectal cancer. in Cancer 2008
Immunostaining analyses in psoria (show VEGFA Antibodies)sis skin lesions suggested that the ectodomain shedding of LYVE-1 occurred in lymphatic vessels undergoing chronic inflammation. These results indicate that the ectodomain shedding of LYVE-1 might be involved in promoting pathological lymphangiogenesis.
These results demonstrate the prerequisite of a critical LYVE-1 threshold density and show that hyaluronan binding may be elicited in lymphatic endothelium by surface clustering with divalent LYVE-1 mAbs.
We have established a novel, three-protein biomarker panel that is able to detect patients with early-stage pancreatic cancer in urine specimens:LYVE-1, REG1A (show REG1A Antibodies), and TFF1 (show TFF1 Antibodies) were selected as candidate biomarkers
Data (including data from studies in knockout mice) suggest LYVE1 mediates adhesion of group A Streptococci (GAS) to lymphatic vesicular endothelium via capsular hyaluronan; this appears to be critical factor for lymphatic trafficking of GAS in vivo.
High expression of LYVE-1 is associated with atherosclerotic arteries.
Data indicate that detection of lymphatic vascular invasion (LVI) can be optimized by specific D2-40 or LYVE-1 staining.
High-low cell surface HA content of tumor cells through the interaction with LYVE-1 leads to adhesion differences.
FGF2 (show FGF2 Antibodies) binds to LYVE-1 with a higher affinity than any other known LYVE-1-binding molecules, such as hyaluronan or PDGF (show PDGFA Antibodies)-BB. Glycosylation of LYVE-1 is important for FGF2 (show FGF2 Antibodies) binding.
CRSBP-1-associated fibrillar structures are identical to the ER network as evidenced by the co-localization of CRSBP-1 and BiP (show GDF10 Antibodies) in these cells
LYVE-1 may have value as predictor of outcome in neuroblastoma (show ARHGEF16 Antibodies)
the LYVE-1-expressing cells might be involved in the uptake of hyaluronan and other waste products as well as foreign particles circulating in the blood and lymph while participating in the subsequent degradation in relay with adjacent macrophage populations.
Immunostaining analyses in VEGF-A (show VEGFA Antibodies) transgenic skin suggested that the ectodomain shedding of LYVE-1 occurred in lymphatic vessels undergoing chronic inflammation. These results indicate that the ectodomain shedding of LYVE-1 might be involved in promoting pathological lymphangiogenesis.
Endogenous hyaluronan on the surface of macrophages can engage LYVE-1, facilitating their adhesion and transit across lymphatic endothelium.
MT1-MMP (show MMP14 Antibodies) directly cleaves LYVE-1 on lymphatic endothelial cells to inhibit LYVE-1-mediated lymphangiogenic responses and restrains the production of VEGF-C (show VEGFC Antibodies).
Data (including data from studies in knockout mice) suggest Lyve1 mediates adhesion of group A Streptococci (GAS) to lymphatic vesicular endothelium via capsular hyaluronan; this appears to be critical factor for lymphatic trafficking of GAS in vivo.
Data show that the expression of lymphatic vessel endothelial hyaluronan receptor 1 (LYVE 1) was similar with vascular endothelial growth factor C (VEGF-C (show VEGFC Antibodies)), but its peak appeared 1-2 d later than that of VEGF-C (show VEGFC Antibodies).
LMW-HA may play a critical role in the processes required for lymphangiogenesis through interactions with its receptor LYVE-1 and triggering intracellular signal cascades.
Studied the specific targeting property of lymphatic vessel endothelial hyaluronan receptor-1 binding polyethylene glycol-coated ultrasmall superparamagnetic iron oxide (LYVE-1-PEG (show PAEP Antibodies)-USPIO) nanoparticles to mouse lymphatic endothelial cells.
Reelin (show RELN Antibodies)-deficient mice showed abnormal collecting lymphatic vessels, characterized by a reduced number of SMCs, abnormal expression of lymphatic capillary marker lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), and impaired function
report intact CD31 (show PECAM1 Antibodies)(+) corneal lymphatic capillary endothelial cells that do not express LYVE-1. The number of LYVE-1(-) gaps initially increased until 8 wk of age but was significantly reduced in aged mice.
CRSBP-1 plays a role in autocrine regulation of cell growth mediated by growth regulators containing cell surface retention sequence.
This gene encodes a type I integral membrane glycoprotein. The encoded protein acts as a receptor and binds to both soluble and immobilized hyaluronan. This protein may function in lymphatic hyaluronan transport and have a role in tumor metastasis.
lymphatic vessel endothelial hyaluronan receptor 1
, extracellular link domain containing 1
, lymphatic endothelial hyaluronan receptor LYVE-1
, lymphatic vessel endothelial hyaluronic acid receptor 1
, cell surface retention sequence binding protein-1
, cell surface retention sequence-binding protein 1
, extracellular link domain-containing 1
, extracellular link domain-containing protein 1
, hyaluronic acid receptor
, extra cellular link domain-containing 1
, lymphatic vessel endothelial HA receptor-1
, lymphatic vessel endothelial HA recptor-1